TICKERNERD
Menu
ECORECORHealthcare · Medical Devices

ECOR Stock Forecast: electroCore, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$10
+1.42% on the day

The 5 Wall Street analysts covering electroCore, Inc. hold a median 12-month price target of $20 — +91.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$94.8M
Ticker Nerd rank
54 / 100
Median analyst target
$20
Analysts covering
5
Total return, dividends reinvested
1W
+3.9%
1M
+61.8%
YTD
+130.9%
1Y
+103.8%
From 52W high
−4.2%
From 52W low
+134.3%
$4
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ECOR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores electroCore, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
54 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
83
Size
76
Momentum
65
Accruals
57
Quality
54
Growth
44
Value
42
Volatility
17
Issuance
7

Revisions (83): Analysts have, on balance, been raising their forecasts.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ECOR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ECOR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25Oct 25Jan 26Apr 26Jul 26ECORHigh $26Median $20Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $12Median $20High $26

The green dot is the last close — the median target sits +91.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
26 Jan 2026HC Wainwright & Co.MaintainsBuy$25 → $18
26 Jan 2026HC Wainwright & Co.MaintainsBuy—
13 Mar 2025HC Wainwright & Co.ReiteratesBuy—
13 Mar 2025Ladenburg ThalmannMaintainsBuy—
18 Dec 2024HC Wainwright & Co.MaintainsBuy—
14 Mar 2024HC Wainwright & Co.ReiteratesBuy—
22 Jan 2024HC Wainwright & Co.MaintainsBuy—
9 Nov 2023HC Wainwright & Co.MaintainsBuy—
10 Aug 2023HC Wainwright & Co.ReiteratesBuy—
4 May 2023HC Wainwright & Co.MaintainsBuy—
18 Apr 2023CG CapitalReiteratesOutperform—
18 Apr 2023HC Wainwright & Co.MaintainsBuy—
9 Mar 2023HC Wainwright & Co.ReiteratesBuy—
13 Jan 2023Brookline CapitalInitiatesBuy$1.25
19 Jan 2022HC Wainwright & Co.MaintainsBuy$3.00 → $2.75
27 July 2021Ladenburg ThalmannInitiatesBuy—
23 Oct 2020Brookline CapitalInitiatesBuy—
30 Sept 2020Maxim GroupInitiatesBuy—
14 Aug 2020BTIGUpgradeBuy—
14 Aug 2020HC Wainwright & Co.MaintainsBuy$2.50 → $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ECOR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ECOR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

electroCore, Inc. (ECOR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.4×

Cheaper than 91% of US stocks

Price / sales
2.6×

Cheaper than 47% of US stocks

Price / book
−35.5×

Cheaper than 99% of US stocks

EV / EBITDA
−6.9×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
28.0%

Higher than 77% of US stocks

Earnings growth (YoY)
28.0%

Higher than 65% of US stocks

Gross margin
86.5%

Higher than 95% of US stocks

Operating margin
−29.3%

Higher than 19% of US stocks

Net margin
−40.0%

Higher than 11% of US stocks

Returns & dividend
Return on equity
817.2%

Higher than 99% of US stocks

Return on assets
−55.0%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ECOR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ECORelectroCore, Inc.$94.8M
54
HYPRHyperfine, Inc.$95.7M
56
LUNGPulmonx Corp.$93.2M
74
MBOTMicrobot Medical, Inc.$100.7M
15
LNSRLENSAR, Inc.$103.6M
60
SERASera Prognostics, Inc.$83.8M
40
RPIDRapid Micro Biosystems, Inc.$83.7M
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own electroCore, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ECOR news & analysis

electroCore, Inc. (ECOR) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

electroCore, Inc. (ECOR) held its Q2 2026 earnings call, the transcript of which was published on Seeking Alpha. The call covered the company's second-quarter 2026 financial results and business update.

Why it matters — A transcript of the Q2 2026 earnings call provides ECOR watchers with a detailed account of management's commentary on the company's recent performance and outlook. Can I add more? The instruction says why_it_matters 1 sentence. That seems fine. But I should keep neutral. Good.

electroCore Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

electroCore reported second-quarter 2026 revenue of $9.5 million, up about 28% from $7.4 million a year earlier, driven by growth in Veterans Affairs prescription sales and direct-to-consumer Truvaga sales. The company raised its full-year revenue outlook to growth of more than 30% over 2025 and said it is targeting positive adjusted EBITDA in the third quarter of 2027.

Why it matters — The revenue growth, raised full-year outlook, and adjusted EBITDA target indicate improving financial momentum for ECOR watchers.

electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 7 Aug 2026positive

electroCore reported a Q2 loss of $0.33 per share, narrower than the Zacks Consensus Estimate of a $0.41 loss and improving on the $0.35 per share loss from a year ago. The company also topped revenue estimates for the quarter.

Why it matters — A narrower-than-expected loss and revenue above consensus indicate the company is performing better than analysts projected, which ECOR watchers would view favorably.

electroCore Announces Second Quarter 2026 Financial Results

GlobeNewsWire · 6 Aug 2026positive

electroCore reported second quarter 2026 net sales of $9.5 million, a 28% increase over the prior year, while its net loss narrowed to $3.1 million, a 17% improvement. The company raised its 2026 revenue guidance to greater than 30% year-over-year growth.

Why it matters — The results show accelerating revenue growth and narrowing losses, leading the company to raise its full-year revenue guidance.

electroCore to Participate in Upcoming Investor Conferences

GlobeNewsWire · 3 Aug 2026neutral

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced that its management will participate in upcoming investor conferences, as reported in a press release on August 3, 2026. No additional details about the conferences were provided in the announcement.

Why it matters — An ECOR watcher would care because these investor conference appearances give management a platform to present the company's business, potentially drawing attention from the investment community.

FAQ

Frequently asked questions about ECOR stock

What is the ECOR stock price forecast for 2026-2027?

The 5 Wall Street analysts covering electroCore, Inc. have a median 12-month price target of $20, with estimates ranging from $12 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ECOR stock a buy right now?

Of the 5 analysts covering electroCore, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks electroCore, Inc. 54 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ECOR?

As at 22 Aug 2026, electroCore, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (83 of 100).

Will ECOR stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +91.7% from the last close, and Ticker Nerd's factor model ranks electroCore, Inc. 54 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ECOR stock forecast for 2030?

No analyst covering electroCore, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ECOR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $26 over the next 12 months.

How has ECOR stock performed over the past year?

electroCore, Inc. returned +103.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does electroCore, Inc. do?

ElectroCore, Inc. is a bioelectronic medicine and general wellness company specializing in non-invasive vagus nerve stimulation (nVNS) technology platforms.

What is the latest news on ECOR?

The most recent item we track (Seeking Alpha, 7 Aug 2026): "electroCore, Inc. (ECOR) Q2 2026 Earnings Call Transcript". electroCore, Inc. (ECOR) held its Q2 2026 earnings call, the transcript of which was published on Seeking Alpha. The call covered the company's second-quarter 2026 financial results and business update.

Company

About electroCore, Inc.

ElectroCore, Inc. is a bioelectronic medicine and general wellness company specializing in non-invasive vagus nerve stimulation (nVNS) technology platforms. Its primary product, gammaCore, is a prescription-only handheld device designed for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for hemicrania continua and paroxysmal hemicrania. The company also offers Truvaga 350 and Truvaga Plus, consumer electronics general wellness products for personal use, with the latter featuring app-enabled functionality. Additionally, ElectroCore provides TAC-STIM for human performance enhancement and gammaCore Sapphire, a portable, reusable, rechargeable prescription device for various primary headache conditions. It has expanded its portfolio through the acquisition of NeuroMetrix, incorporating the Quell platform to address chronic pain and wellness markets. Operating in the United States, United Kingdom, and internationally, ElectroCore focuses on neurology, pain management, and wellness sectors, delivering drug-free therapies via innovative neuromodulation devices. Founded in 2005 and headquartered in Rockaway, New Jersey, the company plays a key role in advancing non-invasive bioelectronic treatments.

CEO Mr. Daniel S. Goldberger · 83 employees · United States · https://www.electrocore.com